Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVATION 1: IMNN-001 + Neoadjuvant Chemo in Ovarian Cancer
NCT02480374Phase 1Completed
- Sponsor
- Imunon, Inc.
- Start
- Sep 2015
- Primary completion
- May 2017
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMNN-001 in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Imunon, Inc. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Sep 2015; status: completed.
02
Drugs
IMNN-001
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02480374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480374.